Login / Signup

Effects of intravitreal bevacizumab in Gram-positive and Gram-negative models of ocular inflammation.

J Daniel LafreniereJames T ToguriRishi R GuptaArif SamadDan M O'BrienJohn DickinsonAlan CruessMelanie E M KellyMark E Seamone
Published in: Clinical & experimental ophthalmology (2019)
Within a 6-hour window bevacizumab had anti-inflammatory actions that were distinct in both Gram-positive (PIU) and Gram-negative (EIU) models, respectively. Given our findings, this would suggest that bevacizumab may have utility as an adjunctive therapy to IVT antibiotics and vitrectomy in the management of exogenous endophthalmitis.
Keyphrases